Clinicians treating papillary thyroid cancer must consider many factors to determine the best treatment for you. One of the most important factors they must consider is their estimate of the likelihood that the cancer will return (also known as risk recurrence). This is because cancers with a high risk of recurrence are treated more aggressively. Estimating the chances that the cancer will come back is difficult.

Thyroid GuidePx® is a molecular test that makes risk estimation simple and accurate.

The incidence of thyroid cancer is increasing by about 6% per year.  Papillary thyroid cancer, the most common type of thyroid cancer, is not usually life-threatening. Still, recurrence after treatment can significantly affect the quality of life.

Identifying high-risk individuals helps to direct appropriately aggressive treatment to those who need it. At the same time, confidently identifying individuals with a very low risk of recurrence will help select when more conservative treatment can be offered.

Qualisure Dx is committed to providing all patients with access to Thyroid GuidePx®.

We proudly offer support by our Reimbursement Navigator  to help guide you through the process of paying for molecular testing.

Our Reimbursement Navigator will explain available options or payments including our financial assistance program 

email: admin@qualisuredx.com

Need more information? Get in touch!

1. Access requisition form by clicking here.
2. Print off requisition form.
3. Fax completed form to Protean BioDiagnostics at (877) 764-7628.
4. A Protean team member will confirm receipt of the test requisition form by email or phone call and discuss your next steps.